# A First in Human Study to Evaluate the Safety and Immunogenicity of RBM-001 in Healthy Adult Volunteers

> **NCT06878170** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Rock BioMedical, Inc.** · enrollment: 60 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** RBM-001

## Key facts

- **NCT ID:** NCT06878170
- **Lead sponsor:** Rock BioMedical, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-09-30
- **Primary completion:** 2025-05-30
- **Final completion:** 2026-01-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06878170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06878170, "A First in Human Study to Evaluate the Safety and Immunogenicity of RBM-001 in Healthy Adult Volunteers". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT06878170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*